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Phospholamban (PLN) plays a central role in Ca2+ homeostasis in
cardiac myocytes through regulation of the sarco(endo)plasmic re-
ticulum Ca2+-ATPase 2A (SERCA2A) Ca2+ pump. An inherited mu-
tation converting arginine residue 9 in PLN to cysteine (R9C) results
in dilated cardiomyopathy (DCM) in humans and transgenic mice,
but the downstream signaling defects leading to decompensation
and heart failure are poorly understood. Here we used precision
mass spectrometry to study the global phosphorylation dynamics
of 1,887 cardiac phosphoproteins in early affected heart tissue in a
transgenic R9C mouse model of DCM compared with wild-type
littermates. Dysregulated phosphorylation sites were quantified
after affinity capture and identification of 3,908 phosphopeptides
from fractionated whole-heart homogenates. Global statistical en-
richment analysis of the differential phosphoprotein patterns
revealed selective perturbation of signaling pathways regulating
cardiovascular activity in early stages of DCM. Strikingly, dysregu-
lated signaling through the Notch-1 receptor, recently linked to
cardiomyogenesis and embryonic cardiac stem cell development
and differentiation but never directly implicated in DCM before,
was a prominently perturbed pathway. We verified alterations in
Notch-1 downstream components in early symptomatic R9C trans-
genic mouse cardiomyocytes compared with wild type by immuno-
blot analysis and confocal immunofluorescence microscopy. These
data reveal unexpected connections between stress-regulated cell
signaling networks, specific protein kinases, and downstream effec-
tors essential for proper cardiac function.
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Cardiovascular diseases (CVDs) leading to systolic/diastolicheart failure (HF), such as hypertensive/diabetic heart dis-
ease, stroke, and vascular atherosclerosis, are leading causes of
death in the developed world (1). Many CVDs are associated
with genetic predispositions. For example, in humans, the argi-
nine to cysteine (R9C) substitution in phospholamban (PLN) has
been shown to result in dilated cardiomyopathy (DCM) pre-
senting in adolescence, leading to rapid deterioration of heart
function and premature death (2). However, the etiology and
molecular mechanisms of progression of DCM and other
CVDs leading to HF are complex and still poorly understood,
further complicating clinical assessment and management.
From a biological and clinical perspective, the identification
and characterization of clinically relevant, potentially drug-
gable, pathways driving the maladaptive response in affected
heart tissue are key challenges to improved diagnostic and
therapeutic tools for earlier detection and preventative treat-
ment of both inherited and chronic CVDs.
Cardiac muscle contraction is controlled by Ca2+ flux and signaling
relays, which are perturbed in HF. Internal stores of Ca2+ required
for the proper functioning of cardiomyocytes (CMs) are normally
maintained through the function of the sarco(endo)plasmic retic-
ulum Ca2+-ATPase 2 (SERCA2) (3), which is responsible for the
sequestration of Ca2+ resulting in muscle relaxation. SERCA2 ac-
tivity is regulated through a reversible inhibitory interaction with
PLN, which can be relieved by phosphorylation of PLN by protein
kinase A (PKA) or Ca2+/calmodulin-dependent protein kinase II
(CaMKII) (3).
Proteomic analyses have revealed changes in the abundance
of other effector proteins in diverse biochemical pathways in
DCM. Notably, shotgun proteomic analysis of membrane pro-
tein expression dynamics in heart microsomes isolated from mice
overexpressing a superinhibitory (I40A) mutant of PLN revealed
changes in G protein-coupled receptor-mediated pathways leading
to activation of protein kinase C (PKC) (4). We previously reported
quantitative changes in protein and cognate mRNA expression
levels in cardiac ventricular tissue at different time points in the
development of DCM in R9C-PLN mice representing clear clinical
stages in the progression to HF (5). We showed that the latter mal-
adaptive response was driven by elevated activity of MAPK signaling
by the protein kinases p38 and JNK, in part through down-regulation
of prosurvival microRNAs (6). However, the underlying upstream and
downstream signaling events preceding HF were not fully explored.
In the present study, we report a systematic, large-scale quan-
titative phosphoproteomic analysis of dysregulated protein phos-
phorylation-dependent signaling occurring at the early symptomatic
stages of DCM progression in whole hearts from R9C mutant mice
compared with wild-type littermates.
Significance
The present study demonstrates the utility of global phospho-
proteomic profiling of diseased cardiac tissue to identify signaling
pathways and other biological processes disrupted in cardiomy-
opathy. Perturbed Notch-1 signaling was identified by bioinfor-
matics analyses of phosphoprotein patterns present in affected
cardiac tissue in a transgenic mouse model system of dilated
cardiomyopathy and by complementary molecular biology and
microscopy techniques. In addition, dozens of other disturbed
signaling pathways offer an opportunity for novel therapeutic
and/or diagnostic clinically applicable targets. Although this study
was performed in mice, only minor adjustments to the experi-
mental approach would be required for comparative analysis of
analogous samples from human cardiac patients, potentially
leading to even more clinically relevant data.
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Results
Comparative Phosphoproteome Analysis.To achieve a comprehensive
survey of cardiac signaling cascades impacted by DCM, we per-
formed global quantitative phosphopeptide profiling on three in-
dependent biological replicates of whole-heart tissue isolated from
8-wk-old (early symptomatic) R9C mice and wild-type littermates
(Fig. 1). A major experimental consideration was preservation of
phosphorylation-site integrity, through use of phosphatase inhibi-
tors, low temperature, and harsh denaturing sample-processing
conditions. To achieve the deepest possible coverage, we per-
formed chromatographic sample prefractionation steps, using hy-
drophilic interaction liquid chromatography to separate peptides
bearing negatively charged phosphate moieties (7). Given the low
relative abundance of phosphopeptides and their tendency to be
undetectable due to ion competition/suppression during MS anal-
ysis, we performed differential affinity capture with immobilized
metal oxide affinity chromatography (TiO2) to enrich for phos-
phopeptides. To measure differences in relative abundance, we
applied label-free quantification, comparing the extracted parent-ion
current intensities recorded in high-energy collision dissociation
(HCD) spectra using a high-precision orbitrap instrument. In par-
allel, we measured total protein levels by shotgun sequencing.
In total, our stringent data analysis workflow (Fig. S1) mapped
94,956 and 217,092 spectra to mouse reference protein sequences
for the phosphoproteomic and background proteomic datasets,
respectively. From this, we derived a set of high-confidence se-
quence matches [false discovery rate (FDR) ∼1% at both protein
and peptide levels] corresponding to over 1,800 cardiac phos-
phoproteins and 3,900 phosphopeptides in normal and DCM
hearts, and 15,436 unique peptides mapping to 3,580 unique
proteins in the background proteomic dataset (Fig. 2 A and B,
Fig. S1, and Datasets S1–S3). For the former, we confidently
(site-localization probability >0.7, as described in SI Materials
and Methods and Datasets S4 and S5) identified 7,589 unique
putative phosphorylation sites (i.e., sites on identified phospho-
peptides with supporting MS/MS data and localization proba-
bility >0.7), of which 6,855 mapped to serine, 674 mapped to
threonine, and 60 mapped to tyrosine residues (consistent with
the expected 90:9:1 cellular distribution ratios) on 1,848 distinct
cardiac proteins (Fig. 2 A and B and Datasets S1 and S2). Our
coverage is comparable to a pioneering study of the mouse
cardiac phosphoproteome by Lundby et al. (8) and a recent
phosphoproteomic analysis of in vivo effects of CaMKII in-
hibition in mouse hearts (9). Phosphoproteins identified in our
study also showed considerable overlap with heart and other
tissue profiles in the mouse phosphoproteomic atlas reported by
the Gygi group (10), but 333 were uniquely identified in our
study, 96 of which contained phosphopeptides significantly al-
tered and/or solely identified in R9C hearts (Fig. 2C). A high
degree of overlap with the mouse ventricular myocyte proteome
by Sharma et al. (11) was also observed (Fig. 2D).
Quantification and Ranking. Based on reproducible measurements
of precursor-ion intensity, we scored both the individual phos-
phopeptides and their consolidated cognate phosphorylation
sites for differential relative abundance between the healthy and
diseased samples. Based on a two-tailed Student’s t test (P < 0.05),
the abundance of 211 phosphopeptides was differentially altered
(elevated or reduced) between the R9C and WT hearts (Fig. 2A
and Dataset S1), with 86% of these predominantly higher in the
disease state. In comparison, 499 proteins showed differential ex-
pression, consistent with our previous report (5).
Systematic evaluation of the corresponding biological annota-
tions revealed that the aberrant phosphorylation patterns occurred
on proteins linked to disparate subcellular compartments, ranging
from membrane-associated receptors to nuclear-localized proteins
with established links to heart development, contractile function,
and/or cardiomyopathy (Dataset S1). Consistent with expectation,
the predominant phosphoform of PLN detected preferentially
in R9C hearts was phosphorylated on serine 16, a site critical for
inhibition of SERCA2 activity (3). We also detected alterations in
the phosphorylation pattern of central kinases involved in cardiac
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Fig. 1. General phosphoproteomics workflow. Three pooled hearts from
R9C-PLN transgenic and wild-type littermates were analyzed by quantitative
precision LC-MS/MS. PTM, posttranslational modification.
Fig. 2. (A) Volcano plot indicating significantly altered proteins and phos-
phoproteins identified in the combined datasets. Log-transformed P values
(t test) associated with individual peptides and phosphopeptides plotted
against log-transformed fold change in abundance between the R9C-PLN and
wild-type hearts. (B) Venn diagram depicting the total number of proteins
identified in the corresponding proteomic and phosphoproteomic datasets.
(C) Venn diagram depicting phosphoprotein overlap with mouse tissue
phosphoproteomes from Huttlin et al. (10). (D) Venn diagram depicting the
overlap of the R9C and WT combined phosphoproteome and proteome with
the ventricular cardiomyocyte proteome from Sharma et al. (11).
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signaling such as PKA. Additionally, the S112 site on the PKA
type II regulatory beta subunit (PRKAR2B), which results in the
lowering of the activation threshold of PKA (12), increased in
R9C. Additionally, we detected abundance changes in a cardiac
stress marker (FHL1), an indicator of the fetal gene program
(MYH7), markers of ECM remodeling (POSTN, SPARC), and
proteins involved in Ca2+ modulation (SLMAP, CASQ2) (Data-
sets S1 and S2).
Further examples of interest include the highest-ranked phos-
phorylated peptide (S64 + T69) from eIF4E-binding protein 1
(EIF4EBP), which negatively regulates translation initiation.
Hypophosphorylated EIF4EBP acts as a repressor of eIF4E
whereas its phosphorylation releases eIF4E, thereby up-regulating
protein translation in response to signaling by diverse cell-surface
receptors, including insulin, EGF, PDGF, and other ligands (13).
In heart, EIF4EBP has been implicated in ischemia–reperfusion
stress, cardiomyocyte survival, cardiac hypertrophy, and oxidative
and nutritional stress responses (13).
Also significantly more highly phosphorylated in R9C hearts
was a previously uncharacterized T187 site in EMMPRIN (BSG/
CD147), an extracellular metalloprotease-inducing member of
the Ig superfamily, consistent with its role in inflammatory pro-
cesses in cardiac remodeling (14). In addition, the S2 phospho-
site on transcription factor MAX (Myc-associated factor X) (15),
a positive regulator of cardiac alpha-myosin heavy-chain gene
expression in cardiomyocytes, was significantly altered in R9C
mice. Phosphorylation of S2 inhibits DNA binding by MAX
homodimers and association with MYC but is not known to af-
fect its interaction with another cofactor, transcription enhancer
factor 1 (TEF-1, TEAD1), or regulation of cardiac alpha-myosin
heavy chain (16). In contrast, when phosphorylated, the S73 site
of transcription factor JUN, likewise more highly phosphorylated
in the R9C mutant mice, is linked to increased transcription of
JUN target genes encoding components of a myriad of signaling
pathways (17).
Phosphosites on two intercalated disk-associated Xin repeat
proteins (XIRP1, XIRP2) with roles in cardiac development
were also increased significantly in R9C hearts. XIRPs interact
with catenins and ion channels in mature cardiac muscle and,
although the significance of phosphorylation is unclear, gene
knockout mice display early-onset cardiomyopathy (18).
Kinase Target Motif Analysis. We used the MotifX algorithm (19)
to identify consensus motifs overrepresented in the set of phos-
phopeptides identified exclusively in R9C heart tissue and/or those
showing significant (P < 0.05) differential expression between
R9C and wild-type mice (Table 1 and Dataset S1). Candidate
consensus sequences were processed using PhosphoMotif Finder
(20) to identify cognate kinases known or predicted to phos-
phorylate these sequences.
We found central kinases involved in cardiac contractility
through transient Ca2+ regulation among the most overrepresented
compared with the whole mouse proteome. Two consensus motifs
identified were targeted by PKA and CaMKII (Table 1), one
enriched 4.76-fold (59 matches) over background and the other
5.64-fold (34 matches). Phosphorylation of PLN by PKA on S16, or
by CaMKII on T17, reverses PLN-mediated inhibition of SERCA2a
activity up to 3-fold during β-adrenergic stimulation (3). Up-
regulation of these kinases is expected as a compensatory mech-
anism considering that R9C-PLN mutant molecules effectively trap
PKA, inhibiting phosphorylation of wild-type protein and relieving
SERCA2a inhibition (2).
Two consensus sequences targeted by extracellular signal-
regulated kinases (ERK1/2) were identified on 275 significantly
altered phosphopeptides (Table 1). ERK1/2 become activated in
cardiac myocytes in response to a variety of stimuli, including
progression of DCM (21). Likewise, we found consensus motifs
associated with phosphorylation by casein kinases and GSK3
kinases, previously linked to cardiac pathology (22).
Pathway Network Enrichment Analysis. For each phosphoprotein
(and corresponding gene), the most differential peptide or mod-
ification site was selected for a systematic pathway enrichment
analysis (SI Materials and Methods). Phosphopeptides were ini-
tially ranked based on the level of statistical significance (differ-
ential P value) rather than direction (up/down) of observed fold
change. The focus of this analysis was to identify pathway-level
alterations present in R9C mice compared with controls.
Three sets of enrichment analyses were performed to gain the
most complete coverage, based on ranking (i) the phosphopro-
teomic dataset alone, (ii) the background proteomic dataset alone,
and (iii) a merged combination of both (Fig. 2 A and B and Fig.
S1), which included the significant differentially abundant proteins
derived from both the proteomic background and differential
phosphorylation events. This merged set of 4,345 unique proteins/
genes (Fig. 2B) was included because signaling perturbations do
not necessarily consist only of changes in phosphorylation state or
protein expression alone but often rather both in concert. The
most differentially expressed peptides or phosphorylation events
(based on P value) from each protein were used to represent in-
dividual protein/gene products. The majority of enriched pathways
found in the merged set (Dataset S3) reflected the presence of
many proteins exclusively in the background proteome. Of the
2,039 gene sets enriched in the merged set, many (1,427) were
likewise enriched in the global proteomic data alone (Fig. S1).
We chose to focus on a subset of 612 pathways and processes
that reflected contributions from both datasets, rather than
merely differential protein levels. To simplify analysis by mini-
mizing redundancy in the annotation term labels (Dataset S1),
we combined the 182 enrichments from the phosphoproteomic
dataset (not in the background proteome) with the 526 gene sets
unique to the merged set (Fig. S1 and Dataset S3). By visualizing
the resulting 708 enriched gene sets as a single graphical enrich-
ment map (23) (Dataset S6), we identified several dysregulated
Table 1. Top 10 ranked identified consensus motifs on phosphopeptides significantly altered
and/or exclusively detected in R9C heart tissue with kinases predicted to target these sequences
Motifs Kinase Motif score Matches Fold increase
...RS.S...... CamKII, PKA, PKC, CK2 27.34 59 4.76
......SD.E... CK2 24.66 34 6.77
....SPT...... GSK3, ERK1/2, CDK5, CK2, DNA-PKCs 23.7 27 7.75
.R..S.S...... CamK2, PKA, PKC, CK2 23.62 34 5.64
....SDS...... CK2, BARK 17.65 21 6.41
......SP.... GSK3, ERK1/2, CDK5 16 275 2.34
...S..S...... CK1/2 16 258 1.74
...R..S...... CamK2, PKA, PKC 12.45 123 2.01
......TP..... GSK3, ERK1/2, CDK5 9.46 63 2.35
..S...S...... GPCRK1, MAPKAPK2K, GSK3 8.1 120 1.7
The number of matches in the query set and the fold increase over the normal occurrence of consensus
sequence are also provided.
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pathways of notable relevance to cardiac pathology (Table 2 and
Fig. S2). For instance, reflecting a central role in cardiac physi-
ology and pathology, dysregulated pathways associated with acti-
vation PKA- and cAMP-dependent kinases were prominently
overrepresented in all gene set enrichment analyses (Datasets S1
and S3). Considering the ubiquity of many signaling pathways
across different tissues and cell types, when examined as a whole
(rather than individual components) it is not surprising that most
pathways have associations with other disorders or processes. This
is also partly a bias of existing annotations in curation databases.
To identify disease signatures specifically relevant to DCM, we
integrated and compared these pathways against a recent in-
depth RNA sequencing-based gene expression study of the R9C-
PLN model (Datasets S2 and S7) (24). Specifically, differential
mRNA expression modules in the Seidman study (24) corresponding
to cardiomyocyte and nonmyocyte cardiac cell populations at dif-
ferent stages of disease (represented by six individual nodes) were
tested for overlap with our enrichment map using a stringent Mann–
Whitney test cutoff (P < 0.01). Strikingly, we observed highly sig-
nificant overlap between most of the disrupted biological processes
and signaling pathways noted by the two studies, including (but not
limited to) innate immunity, glucose metabolism, TGF-β signaling,
PPAR signaling, Wnt/β-catenin signaling, and TLR signaling (Dataset
S8). Notably, the general pathways involved in metabolic and profi-
brotic processes determined by the Seidman study to differen-
tiate between DCM and hypertrophic cardiomyopathy (HCM)
were likewise detected as differentially perturbed in R9C hearts
in our merged data.
Notch-1 Signaling. Distinct from the Seidman study, however, we
identified evidence for significant disruption in homeostatic Notch-1
signaling in R9C hearts, with most phosphosites never reported
before in the context of DCM. For instance, uncharacterized sites
on SNW1 and CREBBP, members of the Notch-1 transcription
coactivator complex (25), were hyperphosphorylated in the R9C
mice. Similarly, we detected previously unreported phosphoryla-
tion sites on both MAX and NCOR1/2, components of a down-
stream transcriptional corepressor complex known to inhibit
transcription of Notch target genes (26).
To directly determine the differential state of Notch receptor
signaling, we performed immunoblots (Fig. 3A) using a panel of
antibodies targeting different Notch receptor isoforms (Notch1/3),
activating and inhibiting ligands (DLL1/4, JAGG1/2, NUMB),
processing enzymes (ADAM9/17), and key downstream effector
transcription factors (HEY2, HES3, SOX9). Strikingly, a very
substantive and specific decrease in total Notch-1 receptor levels
was seen in the R9C hearts, whereas levels of Notch-3 receptor
were unchanged (Notch-2 was undetectable, as was the cleaved
Notch-1 intracellular domain).
Of the activating Notch ligands, DLL1 was down-regulated in
R9C whereas JAGG1 showed no change (DLL4 and JAGG2
were not detected). Conversely, DLL3 and NUMB, which can
Table 2. List of select cardiac-relevant signaling pathways, from the gene set enrichment analysis, along with their relevant protein
components, altered in R9C-PLN hearts
Pathway Identified components Cardiac context
Notch-1 signaling hdac7(s178), tle3(s216), snw1(s224,s232),
tmed2, ncor2,* tbl1xr1, tbl1x, ncor1(s2351),
ep300, adam10, crebbp, rbx1, numb,
hdac5(s652), arrb1, rps27a, mib1
Dilated cardiomyopathy, left
ventricular noncompaction, cardiac
development (36, 40)
VIP signaling map3k1(s915), ppp3cb(s469), plcg1(s1263),
nfatc2(s136), prkar2b(s112), prkacb, prkar2a,
prkar1a, nfkb1, ppp3ca
Myocardial fibrosis, diabetic cardiomyopathy,
ischemia–reperfusion (41)
H3-K4 histone methylation ogt, kmt2a, snw1(s224,s232), nipbl(s2652),
bcor(s423), men1, kdm1a, mt2b, dnmt1,*
pml(s449), pygo2(t264), ctbp1, arrb1,
ube2n, wbp2, lpin1
Hypertrophic cardiomyopathy, fetal
gene program (42)
BCR signaling, beta-cell
activation and regulation
mif, irs2(s1165), thoc1(s560), sos1,* orai1,
fas,* sash3,* ptprc(s801), lyn(s19), syk,
itpr1(s1573), cd81, stim1,* ptpn6, nfatc2(s136),
inpp5d(t701, s709), sh3kbp1(s193), aplf(s41),
cbl, plcg1(s1263), tcf3(s517), bad(s112), itpr2,
calm1, pawr, itpr3, bmi1, nck1
Heart failure, hypertrophy, myocardial
fibrosis, myocardial infarction,
ischemia–reperfusion (43, 44)
TGF-β/smad signaling glg1, pdpk1(s117), jun(s63), lemd3, fbn2, men1,
zeb1, aspn, eng, snx6, zfyve9, cav3, sptbn1,
bcl9l, strap, cav2,* ppm1a, htra1
Dilated cardiomyopathy, heart failure,
fibrosis, myocardial infarction, cardiac
remodeling (24, 45)
PPAR-α signaling med19(s226), txnrd1, ankrd1, wwtr1,* abca1(s2234),
yap1, med24,* tbl1xr1, alas1, cdk19, tbl1x,
apoa1, acox1, apoa2, smarcd3, agt, ncoa3,*
ncoa2, nfya(s187), fhl2, sp1, ncoa6, acadm,
acsl1, cd36, crebbp, slc27a1, cpt2, ncor1(s2351),
plin2, me1, ep300
Dilated cardiomyopathy, heart failure,
diabetic cardiomyopathy (24, 46)
TLR signaling hsp90b1(s306), lgmn, ikbkb, map2k1, app, nfkb2(t425),
dhx9(s137), dnm2, ppp2r5d,* unc93b1, dnm1(s774),
itgb2, rps6ka3, eea1, dusp3, tlr3, ctsb, nfkb1, ube2n,
ppp2ca, cd36, mef2a, ppp2r1a
Dilated cardiomyopathy, heart failure,
ischemia–reperfusion, hypertrophy,
viral myocarditis (24, 47)
Wnt signaling scyl2(s253), dab2ip(s854), ranbp3, cdh2, wwtr1,* rapgef1,*
gsk3a, ppp2r3a, mcc,* dab2, limd1, ctnnb1, dact3(s165),
bicc1, gsk3b, stk3(s246), ctnnd1(s813), g3bp1, cav1, ppp2r5a,
pi4k2a(s462), cul3, mapk14,* dvl3,* hdac2(s394)
Dilated cardiomyopathy, fibrosis, heart
failure, myocardial infarction,
arrhythmia (24, 48)
Phosphopeptides/proteins increased in R9C hearts are shown in bold, whereas components identified but showing a decrease in R9C are not bolded. The identified
phosphorylation site of a particular protein is indicated in parentheses. For a full list of protein/gene names associated with each pathway, refer to Datasets S1–S3.
*Proteins annotated as “ambiguous,” as described in SI Materials and Methods.
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suppress Notch signaling, were up-regulated in R9C hearts. Two
metalloproteinases (ADAM9 and TACE/ADAM17) required
for extracellular processing and/or degradation of the Notch-1
receptor were similarly up-regulated in R9C. Conversely, the
downstream Notch-1–regulated transcription factors HES1 and
HEY2 were down-regulated in R9C.
Immunofluorescence visualization of components of the Notch
signaling pathway in the ventricular wall of R9C and wild-type
hearts (Fig. 3B) established down-regulation of Notch-1 receptor
expression in R9C cardiomyocytes along with up-regulation of the
ADAM9 metalloproteinase (Notch-3 was unchanged). Imaris-
based quantification (Fig. 3C) of signal intensity and localization
of the Notch-1 intracellular domain (N1CID) in cardiomyocyte
nuclei, indicative of Notch-1 activation, revealed a significant de-
crease (P < 0.003) in overall nuclear localization of N1CID in cells
in the ventricular sections of R9C hearts compared with controls
(due to gross changes in tissue morphology in R9C hearts, a large
proportion of nuclei showed no N1CID colocalization). These
results verify Notch-1 receptor signaling inhibition in affected
heart tissue during early-stage disease (Fig. 4).
Discussion
During pathological cardiac remodeling, including DCM, disrup-
tions in various signaling cascades have been reported, including
AKT, ERKs, GSK3, JAKs, MAPKs, PI3K, PKA, PKC, and TGF-β.
Activation or inhibition of signaling pathways can ultimately result
in changes to cardiomyocyte cell growth, differentiation, pro-
liferation, and/or survival (27). However, despite advances in un-
derstanding the molecular basis of cardiac disease, a clear global
picture of system-wide signaling network perturbations does not
exist for most conditions, including DCM. To address this gap, we
applied quantitative precision mass spectrometry to glean the
complex interplay of signaling events associated early during dis-
ease progression with a genetic cause of cardiac HF.
One-third of all cardiac proteins are known or predicted to be
phosphorylated. Here, we mapped 7,589 phosphopeptides on 1,848
cardiac proteins, of which 211 were differentially abundant in the
R9C model, providing unprecedented insights into the global
dysregulation of signaling cascades in early-stage DCM. Many sites
we identified are novel and of unknown biological significance.
Although annotated repositories of experimental phosphoproteo-
mic datasets have been established (e.g., PhosphoSitePlus) (28),
establishing relevance to heart biology and CVD is not straight-
forward. Our present study aimed to first identify significantly al-
tered individual phosphosites and then use the corresponding
associated protein/gene annotations in conjunction with information
gained from global proteomic analysis. This design was motivated by
computational tools for signaling network analysis and visualization,
which historically focused on gene expression datasets rather than
individual phosphosites.
One especially intriguing finding was identification of Notch-1
signaling as prominently altered in DCM. The Notch pathway is
a widely studied system crucial to “cell-fate” determination (29).
Mammals express four Notch receptors (Notch-1 to Notch-4)
and five ligands (DLL1/3/4, JAGG1/2) (30). Notch-1 is expressed
across a broad variety of cell types, including cardiomyocytes. All
members of the Notch family are translated as single chains but are
subsequently processed in the Golgi system to produce extracel-
lular and transmembrane subunits that remain bound together at
the plasma membrane by noncovalent bonds. Generally, ligand
binding triggers the selective cleavage and removal of the extra-
cellular subunit by members of the ADAM protease family, fol-
lowed by cleavage of the membrane-bound intracellular subunit by
γ-secretase to release N1ICD, which translocates to the nucleus to
modulate transcription (Fig. 4). However, this oversimplification does
not reflect cell context, as different ligands can act as Notch inhibitors
whereas processing enzymes can oppose Notch activation (29).
Changes in phosphorylation of Notch signaling components
included an uncharacterized phosphorylation site on the polyubiquitin
protein UBB required for homeostatic recycling of Notch-1, which
is up-regulated in R9C mice (31), as well as members of the his-
tone deacetylase family (HDAC4/7/9) and others (32). However,
due to incomplete functional annotation, our cautious conclusion
was that the Notch-1 pathway was disrupted but not the precise
nature of the perturbation (i.e., activation/inhibition).
We verified changes in Notch-1 signaling by immunoblotting
and immunofluorescence. We demonstrated down-regulation of
Notch-1 and DLL1 in R9C. DLL3, a Notch-1 ligand previously
shown to be a cis-acting inhibitor (33), was up-regulated along
with NUMB, whose association with Notch-1 leads to proteasomal
degradation (34). ADAM9 and TACE/ADAM17, normally nec-
essary for activation of Notch-1, were also up-regulated in R9C.
However, excessive expression of these proteases has also been
shown to inhibit Notch signaling, whereas deficiency of a major
associated inhibitor, TIMP3, leads to dilated cardiomyopathy in
mice (35). Furthermore, expression and nuclear localization of
the N1ICD domain of Notch-1 were significantly greater in
wild-type cardiomyocytes compared with R9C. Together, these
results show that Notch-1 signaling is down-regulated in myo-
cardium in early-stage DCM.
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Fig. 3. (A) Immunoblots of components of the Notch-1 signaling pathway.
(B) Immunofluorescence images of Notch-1, ADAM9, and Notch-3 in ventricular
sections of WT and R9C-PLN hearts. (C) Representative reconstructed images
showing nuclear localization of the Notch-1 intracellular domain and a bar graph
showing quantification of relative distribution (spots identified/nuclear volume
as determined by Hoechst staining) in WT and R9C-PLN hearts (mean ± SEM, *P =
0.00282).
Fig. 4. Proposed schematic model of Notch-1 signaling in normal and DCM
cardiomyocytes populated with differential proteins identified with different lines
of evidence in whole-heart lysates or ventricular sections, including proteomic
data, phosphoproteomic data, immunoblotting, and immunofluorescence (IF).
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Our findings are consistent with previous reports of develop-
ment of DCM in vitro and in newborn mice treated with an in-
hibitor of Notch-1–dependent signaling (36), or more pronounced
cardiac dysfunction, fibrosis, and apoptosis in adult hearts from an
agonist-induced hypertrophy model or Notch-1 cardiac-specific
null mice (37). Similarly, transgenic mice overexpressing the
Notch ligand JAGGED1 were protected from pressure overload-
induced cardiac hypertrophy (38).
Considering these unprecedented phosphoproteomics data, it is
clear that a more complete understanding of Notch-1 signaling
and other potentially relevant pathways in adult heart following
injury, including in human patients, is warranted (39). Indeed,
uncoupling of Notch-1 signaling in R9C (Fig. 4) suggests that
Notch-1–activating compounds (i.e., activating antibodies, poly-
peptides, small molecules) may be clinically beneficial under
DCM conditions, similar to that observed in hypertrophy (38) and
potentially other pathological contexts.
Materials and Methods
Transgenic mice carrying the R9C mutation in the PLN gene were previously
described (2) and experiments were approved by the Animal Use Committee
at the University of Toronto. Workflows for heart sample preparation,
processing, and (phospho)proteomic profiling, including chromatographic
fractionation, MS data generation, phosphosite localization and scoring,
statistical enrichment analyses, motif prediction, Western blotting, and im-
munofluorescence, are detailed in SI Materials and Methods and Table S1.
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